Armata Pharmaceuticals, Inc.
ARMP · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.02 | -0.09 | 0.20 |
| FCF Yield | -58.94% | -47.54% | -81.58% | -18.83% |
| EV / EBITDA | -26.88 | -5.60 | -2.12 | -7.29 |
| Quality | ||||
| ROIC | -52.02% | -40.54% | -35.19% | -35.05% |
| Gross Margin | 74.39% | -645.64% | 83.81% | -347.36% |
| Cash Conversion Ratio | 1.99 | 0.69 | 0.88 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.06% | 0.41% | 88.45% | – |
| Free Cash Flow Growth | 29.04% | -60.17% | -39.44% | -30.30% |
| Safety | ||||
| Net Debt / EBITDA | -17.12 | -2.68 | -0.94 | -1.26 |
| Interest Coverage | -3.95 | -15.57 | -1,274.00 | -372.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -158.53 | 253.90 | -558.33 | 223.10 |